Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of CU20060204A7publicationCriticalpatent/CU20060204A7/en
Publication of CU23637B6publicationCriticalpatent/CU23637B6/en
La presente invención se relaciona con un uso de un régimen extendido flexible para la anticoncepción hormonal, útil para tratar problemas de hemorragias asociados con el uso extendido fijo de anticonceptivos hormonales y envase farmacéutico que contiene el respectivo anticonceptivo hormonal.The present invention relates to a use of a flexible extended regimen for hormonal contraception, useful for treating bleeding problems associated with the fixed extended use of hormonal contraceptives and pharmaceutical packaging containing the respective hormonal contraceptive.
CU20060204A2004-04-302006-10-27
TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED ANTI-CONCEPTIVE REGIMES
CU23637B6
(en)
USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
Pharmaceutical composition containing a) 2.0 mg of dienogest and 0.015 mg of ethinylestradiol and (6s) -5-methyl-tetrahydrofolate and one or more excipient / vehicles; kit; use for femeneine contraception and reduce the risk of congenital malformations due to lack of folate in pregnancy.
PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND 17BETA ESTRADIOL; PHARMACEUTICAL KIT THAT INCLUDES SUCH COMPOSITION, USEFUL FOR HORMONAL THERAPY AND CONTRACEPTION IN WOMEN.
Pharmaceutical combination comprising 11b- (4-acetylphenyl) -17b-hydroxy-17 (1,1,2,2,2-pentafluoroethyl) estra-4,9-dien-3-one together with at least one pure non-steroidal antiestrogen ; and use for prophylaxis or treatment of brca1 or brca2 mediated cancer.